Lisinopril vs Pembrolizumab
Lisinopril vs Pembrolizumab: Overview
This comparison examines the pharmacological differences between Lisinopril and Pembrolizumab.
Mechanism of Action
Lisinopril: ACE inhibitor preventing conversion of angiotensin I to angiotensin II.
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Lisinopril — 12 hours; Pembrolizumab — 26 days.
Chemical Properties
Molecular Formula: Lisinopril — C21H31N3O5.
Molecular Weight: Lisinopril — 405.4900 g/mol.
Type: Lisinopril — Small molecule; Pembrolizumab — Antibody.